Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Sara La Gioia"'
Autor:
Michele Romoli, Eleonora Matteo, Ludovica Migliaccio, Mauro Gentile, Maria Giulia Mosconi, Giuseppe Maria Scura, Marcello Naccarato, Enrico Colangeli, Paolo Candelaresi, Vincenzo Andreone, Fabrizio Giammello, Rosa Fortunata Musolino, Cristina Dell’Aera, Federica Nicoletta Sepe, Edoardo Pronello, Leonardo Barbarini, Marcella Caggiula, Federica Rizzo, Marco Petruzzellis, Elisa Giorli, Maria Luisa Zedde, Sabrina Anticoli, Marilena Mangiardi, Mario Muto, Francesco Diana, Maria Vittoria De Angelis, Anna Digiovanni, Letizia Concari, Sara La Gioia, Maria Sessa, Sara Biguzzi, Francesco Cordici, Marco Longoni, Maria Ruggiero, Silvia Cenciarelli, Paolo Eusebi, Simona Sacco, Valeria Caso, Maurizio Paciaroni, Stefano Ricci, Andrea Zini, Danilo Toni, David Giannandrea
Publikováno v:
Eur Stroke J
Introduction: Recent anticoagulant intake represents a contraindication for thrombolysis in acute ischemic stroke. Idarucizumab reverses the anticoagulant effect of dabigatran, potentially allowing for thrombolysis. This nation-wide observational coh
Autor:
Paola Cavalla, Laura Brambilla, Roberta Grasso, Cinzia Cordioli, Alice Laroni, Alessia Giugno, Valentina Torri Clerici, Maria Pia Sormani, Pietro Annovazzi, Francesco Saccà, Eleonora Cocco, Jessica Frau, Elisabetta Signoriello, Antonio Gallo, Marinella Clerico, Stefania Federica De Mercanti, Antonio Carotenuto, Simona Bonavita, Cinzia Valeria Russo, Giuseppe Fenu, Caterina Lapucci, Giorgia Teresa Maniscalco, Arianna Sartori, Francesca Caleri, Marco Capobianco, Alessio Signori, Rosa Iodice, Sara La Gioia, Giacomo Lus, Mauro Zaffaroni, Damiano Baroncini, Valeria Di Francescantonio
Publikováno v:
European Journal of Neurology. 29:257-266
Background and purpose: Real-world data on alemtuzumab are limited and do not provide evidence of its effectiveness after various disease-modifying therapies (DMTs). Our aim was to provide real-world data on the impact of clinical variables and previ
Autor:
Marco Arosio, Manlio Sgarzi, Dario Alimonti, C. Foresti, Riccardo Riva, Barbara Frigeni, Nicola Rifino, Giorgia Camera, Annapaola Callegaro, Bruno Censori, Martina Viganò, Simonetta Gerevini, Stefano Quadri, Emanuela Agazzi, Marcella Vedovello, Tania Partziguian, Benedetta Storti, Virginio Bonito, Maria Cristina Servalli, Marta Zaffira Conti, Maria Grimoldi, Maria Sessa, Elisabetta Venturelli, Sara La Gioia
Publikováno v:
Journal of Neurology
Objectives: Evidences from either small series or spontaneous reporting are accumulating that SARS-CoV-2 involves the Nervous Systems. The aim of this study is to provide an extensive overview on the major neurological complications in a large cohort
Autor:
Matteo Cortinovis, Elisa Raimondi, Federico Pozzi, Alessandro Padovani, Laura Fusi, Federico Carimati, Sonia Bonacina, Mario Grassi, Valentina Mazzoleni, Alessandro Prelle, Anna Magherini, Simonetta Gerevini, Andrea Pilotto, Manuel Corato, Valeria De Giuli, Enrico Premi, Valentina Puglisi, Giorgio Silvestrelli, Francesco Santangelo, Alessia Giossi, Davide Sangalli, Maurizio Versino, Simone Beretta, Giuditta Giussani, Francesca Barbieri, Giampiero Grampa, Rubjona Xhani, Susanna Diamanti, Daria Valeria Roccatagliata, Alfonso Ciccone, Stefano Masciocchi, Elio Agostoni, Nicola Rifino, Massimo Gamba, Maria Sessa, Anna Cavallini, Sara La Gioia, Alberto Benussi, Bruno Censori, Martina Locatelli, Alessandro Pezzini, Andrea Salmaggi, Fernando Palluzzi, Mauro Magoni, Luisa Vinciguerra, Debora Pezzini, Simona Marcheselli, Carlo Ferrarese
Publikováno v:
Journal of Neurology
Objective To characterize patients with acute ischemic stroke related to SARS-CoV-2 infection and assess the classification performance of clinical and laboratory parameters in predicting in-hospital outcome of these patients. Methods In the setting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8a2b27b45d0a5d5b72aff6fd654ac90
http://hdl.handle.net/11383/2121884
http://hdl.handle.net/11383/2121884
Autor:
Domenico Ippolito, Sara La Gioia, Sabrina Esposito, Valentina Torri Clerici, Giorgia Teresa Maniscalco, Cinzia Cordioli, Lorena Pareja-Gutierrez, Elisabetta Signoriello, Cinzia Valeria Russo, Roberta Grasso, Doriana Landi, B. Frigeni, Andrea Visconti, Caterina Barrilà, Valeria Barcella, Raffaella Cerqua, Alice Laroni, Simona Bonavita, Stefania Barone, P. Perini, Sarah Rasia, Arianna Sartori, Maria Laura Stromillo, Roberta Lanzillo, Damiano Baroncini, Jessica Frau, Francesco Saccà, Luigi Lavorgna, Alessio Signori, Ignazio Roberto Zarbo, Giorgia Mataluni, Eleonora Cocco, Maria Pia Sormani, E Binello, Pietro Annovazzi, M Clerico, Simona Pontecorvo, Giuseppe Fenu, Alessia Di Sapio, Anna Maria Repice
ObjectiveCladribine tablets were tested against placebo in randomized controlled trials (RCTs). In this study, the effectiveness of cladribine vs other approved drugs in patients with relapsing-remitting MS (RRMS) was compared by matching RCT to obse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3633ac77440e05d5b3cb5d65d3b1b1
http://hdl.handle.net/11591/435028
http://hdl.handle.net/11591/435028
Autor:
Roberta Grasso, Doriana Landi, Luca Carmisciano, Simona Bonavita, Domenico Ippolito, Sara La Gioia, Marinella Clerico, Cinzia Valeria Russo, A. Repice, Maria Laura Stromillo, Roberta Lanzillo, Raffaella Cerqua, Alice Laroni, Lorena Pareja Gutierrez, Stefania Barone, Maria Pia Sormani, Simona Pontecorvo, E Binello, Pietro Annovazzi, Valentina Torri Clerici, Giorgia Mataluni, Cinzia Cordioli, Elisabetta Signoriello, Jessica Frau, Alessio Signori, Sarah Rasia, Arianna Sartori, Gabriella Turano, Francesco Saccà, Damiano Baroncini, Alessia Di Sapio, Ignazio Roberto Zarbo, Eleonora Cocco, Paola Perini, Luigi Lavorgna, Caterina Barrilà, Giorgia Teresa Maniscalco, B. Frigeni
Background: The approval of an increasing number of disease modifying drugs for the treatment of Multiple Sclerosis (MS) creates new challenges for patients and clinicians on the first treatment choice. The main aim of this study was to assess factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5987f631ad62cedd8ee5703c2a9ed7
http://hdl.handle.net/11588/804418
http://hdl.handle.net/11588/804418
Autor:
Lorenzo Peverelli, Anna Cavallini, Lorenzo Lorusso, Alfonso Ciccone, Sandro Beretta, Antonio Colombo, Mauro Roncoroni, Giampiero Grampa, Maurizio Versino, Irene Colombo, Alessandro Prelle, Sara La Gioia, Elisabetta D'Adda, Carla Zanferrari, Davide Sangalli, Paola Santalucia, Andrea Salmaggi, Donata Guidetti, Simone Beretta, Filippo Martinelli-Boneschi, Simona Marcheselli, Riccardo Altavilla
Publikováno v:
Journal of the Neurological Sciences
Introduction Growing evidence has been published as to the impact of SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) on cerebrovascular events over the last few months, with considerable attention paid to ischemic strokes. Conversely, li
Autor:
Caterina Barrilà, Alice Laroni, Raffaella Cerqua, Giorgia Teresa Maniscalco, Alessia Di Sapio, Jessica Frau, Alessio Signori, A. Repice, Domenico Ippolito, Sara La Gioia, Giuseppe Fenu, Ignazio Roberto Zarbo, Francesco Saccà, Giorgia Mataluni, Sabrina Esposito, Elisabetta Signoriello, Arianna Sartori, Simona Bonavita, Eleonora Cocco, Roberta Lanzillo, Salvatore Lo Fermo, B. Frigeni, Valeria Barcella, Maria Pia Sormani, Simona Pontecorvo, E Binello, Pietro Annovazzi, Sarah Rasia, Cinzia Cordioli, Roberta Grasso, Valentina Torri Clerici, Damiano Baroncini, Lorena Pareja Gutierrez, Luigi Lavorgna, Marinella Clerico, Cinzia Valeria Russo, Fabio Gallo, Francesca Bovis, Silvia Rossi
Background: With many options now available, first therapy choice is challenging in multiple sclerosis (MS) and depends mainly on neurologist and patient preferences. Objectives: To identify prognostic factors for early switch after first therapy cho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee69ec79243d3027d12c7b6bcbd0a86
http://hdl.handle.net/2318/1691461
http://hdl.handle.net/2318/1691461
Autor:
Francesco Saccà, Giuseppe Fenu, Alessio Signori, Sara La Gioia, Simona Bonavita, Jessica Frau, Marinella Clerico, Cinzia Valeria Russo, Marco Capobianco, Arianna Sartori, Maria Pia Sormani, Damiano Baroncini, Pietro Annovazzi, Caterina Lapucci, Eleonora Cocco, Alice Laroni, Antonio Carotenuto, Elisabetta Signoriello, Antonio Gallo, Giorgia Teresa Maniscalco
Background: A high reactivation of multiple sclerosis (MS) was reported in patients treated with alemtuzumab after fingolimod. We aimed to understand whether this shift enhanced the risk for reactivation in a real-life cohort. Methods: Subjects with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc8de24bfb893108c7526a212ef9932
http://hdl.handle.net/2318/1737464
http://hdl.handle.net/2318/1737464
Publikováno v:
SM Musculoskeletal Disorders. 2:1-3